Expected developments in hepatology

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 16, Issue 6, 2002, Pages 957-970

  Forns, Xavier ^a   Sánchez Tapias, José M ^a   Parés, Albert ^a   Llovet, Josep M ^a   Bruix, Jordi ^a   Rodés, Juan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Anti mitochondrial antibodies; Chronic cholestasis; Chronic hepatitis B; Chronic hepatitis C; Hepatocellular carcinoma; Primary biliary cirrhosis; Primary sclerosing cholangitis

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; CHEMICAL AGENT; CHLORPROMAZINE; CISPLATIN; DIHYDRALAZINE; DOXORUBICIN; DRUG; FLUOROURACIL; GLYCYRRHIZIC ACID; HALOTHANE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS C VACCINE; IODINE 131; LAMIVUDINE; MITOCHONDRION ANTIBODY; NUCLEOSIDE ANALOG; OCTREOTIDE; OLTIPRAZ; ORGANIC COMPOUND; PEGINTERFERON; RIBAVIRIN; TAMOXIFEN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VIRUS DNA; XENOBIOTIC AGENT; XIAO CHAI HU TANG; ANTIANDROGEN; HEPATITIS VACCINE; INTERFERON; VITAMIN D;

ANTIBIOTIC RESISTANCE; ARTICLE; AUTOIMMUNITY; BILE DUCT DISEASE; CANCER RISK; CHOLESTASIS; CHRONIC HEPATITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; EVIDENCE BASED MEDICINE; FOLLOW UP; GENE SEQUENCE; GENETIC HETEROGENEITY; GENOTYPE; HEPATITIS B; HEPATITIS C; HEREDITY; HUMAN; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; LONG TERM CARE; NONHUMAN; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY PREVENTION; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; RECURRENT INFECTION; REHABILITATION; SECONDARY PREVENTION; VIRUS MUTANT; VIRUS REPLICATION; WILD TYPE; BILIARY CIRRHOSIS; GASTROENTEROLOGY; LIVER TUMOR; REVIEW; SCLEROSING CHOLANGITIS; ADVANCED CANCER; ALCOHOL CONSUMPTION; ARTIFICIAL EMBOLISM; BACTERIUM CULTURE; BILE DUCT CARCINOMA; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL BASED GENE THERAPY; CELLULAR IMMUNITY; DISEASE ASSOCIATION; DRUG SAFETY; DRUG TOLERABILITY; GENE THERAPY; GENETIC VARIABILITY; HEPATITIS B VIRUS; LIVER BIOPSY; LIVER CIRRHOSIS; MELANOMA; META ANALYSIS; PROTEIN DEGRADATION; PROTON RADIATION; REINFECTION; SYSTEMATIC REVIEW; TUMOR GROWTH;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CHOLANGITIS, SCLEROSING; CHOLESTASIS; GASTROENTEROLOGY; HEPATITIS, CHRONIC; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER NEOPLASMS;

EID: 0347983819     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.2002.0341     Document Type: Article

References (40)

1. Hunt, C M, McGill, J M, Allen, M I, & Condreay, L D (2000). Clinical relevance of hepatitis B viral mutations. Hepatology, 31 1037-1044.
2. Hadziyannis, S J, & Vassilopoulos, D (2001). Hepatitis B e antigen-negative chronic hepatitis B. Hepatology, 34 617-624.
3. Brechot, C, Thiers, V, & Kremsdorsf, D et al. (2001). Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely 'occult'?. Hepatology, 34 194-203.
4. Shouval, D, & Samuel, D (2000). Hepatitis B immune globulin to prevent hepatitis B graft reinfection after liver transplantation. Hepatology, 32 1189-1195.
5. Lok, A SF, Heathcote, E J, & Hoofnagle, J H (2001). Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology, 120 1828-1853.
6. Forns, X, & Bukh, J (1999). The molecular biology of hepatitis C virus. Genotypes and Quasispecies, 3 693-716.
7. Forns, X, Ampurdanés, S, & Sánchez-Tapias, J M et al. (2001). Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. Journal of Hepatology, 35 265-271.
8. Bataller, R, & Brenner, D A (2001). Hepatic stellate cells as a new target for the treatment of liver fibrosis. Seminars in Liver Disease, 21 437-451.
9. Jaeckel, E, Cornberg, M, & Wedemeyer, H et al. (2001). Treatment of acute hepatitis C with interferon alfa-2b. New England Journal of Medicine, 345 1452-1457.
10. Manns, M P, McHutchison, J G, & Gordon, S C et al. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. A randomised trial. Lancet, 358 958-965.
11. Landford, R E, & Bigger, C (2002). Advances in model systems for hepatitis C virus research. Virology, 293 1-9.
12. Keogh, A, Sadamoto, T, & Joplin, R et al. (1999). Expression of pyruvate dehydrogenase complex PDC-E2 on biliary epithelial cells induced by incubation with lymph nodes from primary biliary cirrhosis. Hepatology, 4 469A.
13. Metcalf, J V, Mitchinson, H C, & Palmer, J et al. (1996). Natural history of early primary biliary cirrhosis. Lancet, 348 1399-1402.
14. Haydon, G H, & Neuberger, J (2000). PBC: an infectious disease?. Gut, 47 586-588.
15. Vilagut, L, Vila, J, & Vinas, O et al. (1994). Cross reactivity of anti- Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. Journal of Hepatology, 21 673-677.
16. Vilagut, L, Parés, A, & Viñas, O et al. (1997). Antibodies to mycobacterial 65-kD heat shock protein cross-react with the main mitochondrial antigens in patients with primary biliary cirrosis. European Journal of Clinical Investigation, 27 667-672.
17. O'Donohue, J, Fidler, H, & Garcia-Barcelo, M et al. (1998). Mycobacterial DNA not detected in liver sections from patients with primary biliary cirrhosis. Journal of Hepatology, 28 433-438.
18. Vilagut, L, Parés, A, & Vila, J et al (1994). Mycobacterium gordonae DNA in liver tissue of patients with primary biliary cirrhosis. Journal of Hepatology, 21 S87.
19. Mayo, I, Arizti, P, & Parés, A et al. (2000). Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis. Journal of Hepatology, 33 528-536.
20. Bogdanos, D P, Baum, H, & Sharma, U C et al. (2002). Antibodies against homologous microbial caseinolytic proteases P characterize primary biliary cirrosis. Journal of Hepatology, 36 14-21.
21. Harada, K, Tsuneyama, K, & Sudo, Y et al. (2001). Molecular identification of bacterial 16S ribosomal RNA in liver tissue of primary biliary cirrosis. Is Propionibacterium acnes involved in granuloma formation?. Hepatology, 33 5530-5536.
22. Mason, A L, Xu, L, & Guo, L et al. (1998). Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet, 351 1620-1624.
23. Tanaka, A, Borchers, A, & Ishibashi, H et al. (2001). Genetic and familiar considerations in primary biliary cirrhosis. American Journal of Gastroenterology, 96 8-15.
24. Polson, R J, Portmann, B, & Neuberger, J et al. (1998). Evidence for disease recurrence after liver transplantation for primary biliary cirrhosis: clinical and histological follow up studies. Gastroenterology, 97 715-725.
25. Long, S A, Quand, C, & Van de Water, J et al. (2001). Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. Journal of Immunology, 167 2956-2963.
26. Olsson, R, Bjornsson, E, & Backman, L et al. (1998). Bile duct bacterial isolates in PSC: a study of explanted livers. Journal of Hepatology, 28 426-432.
27. Vierling, J (1998). Aetiopathogenesis of primary sclerosing cholangitis. In P Manns, R W Chapman, A Stiehl, & R Wiesner (Eds.), Primary Sclerosing Cholangitis, 37-45. London: Kluwer Academic.
28. Spurkland, A, Saarinen, S, & Boberg, K M et al. (1999). HLA class II haplotypes in primary sclerosing cholangitis from five European populations. Tissue Antigens, 53 459-469.
29. Mitchell, S A, Grove, J, & Spurkland, A et al. (2001). Association of the TNFα-308 but not the interleukin-10-627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut, 49 288-294.
30. Boberg, K, Rocca, G, & Egeland, T et al. (2002). Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology, 35 652-657.
31. Parkin, D M, Bray, F, Ferlay, J, & Pisani, P (2001). Estimating the world cancer burden: GLOBOCAN 2000. International Journal of Cancer, 94 153-156.
32. Bruix, J, Sherman, M, & Llovet, J M et al. (2001). Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. Journal of Hepatology, 35 421-430.
33. Bruix, J, & Llovet, J M (2002). Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology, 35 519-524.
34. Buendia, M A (2000). Genetics of hepatocellular carcinoma. Seminars in Cancer Biology, 10 185-200.
35. Llovet, J M, Fuster, J, & Bruix, J (1999). Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection vs transplantation. Hepatology, 39 1434-1440.
36. Kojiro, M, & Nakashima, O (1999). Histopathologic evaluation of hepatocelluar carcinoma with special reference to small early tumors. Seminars in Liver Disease, 19 287-296.
37. Castells, A, Bruix, J, & Brú, C et al. (1995). Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology, 109 917-922.
38. GETCH. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. New England Journal of Medicine 1995; 332: 1256-1261.
39. Llovet, J M, Real, M, & Vilana, R et al. (2002). Arterial embolization, chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet, 359 1734-1739.
40. Bordignon, C, & Roncarolo, M (2002). Therapeutic applications for hematopoietic stem cell gene transfer. Nature Immunology, 3 318-321.